logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Archemix Corporation

USPTO Granted Patents = 24

% Expired Patents = 45.8



Forward Citations = 312

Loading Chart...
Loading Chart...

31 inventors (with patents filed for the assignee):

goldMedal John Louis Diener (15 out of 34 patents)

silverMedal Charles Wilson (15 out of 16 patents)

bronzeMedal David Epstein (12 out of 15 patents)

4.  Thomas Greene McCauley (12 out of 14 patents)

5.  Claude Benedict (11 out of 12 patents)

6.  Markus Kurz (11 out of 18 patents)

7.  Jeffrey C Kurz (9 out of 12 patents)

8.  James Rottman (8 out of 12 patents)

9.  Dilara McCauley (6 out of 44 patents)

10.  Dilara Grate (5 out of 5 patents)

11.  Kristin Thompson (4 out of 4 patents)

12.  H A Daniel Lagassé (4 out of 4 patents)

13.  Paul Hatala (3 out of 16 patents)

14.  Sara Chesworth Keene (3 out of 3 patents)

15.  Anthony Dominic Keefe (3 out of 12 patents)


24 patents:

1. 10947544 - Aptamer therapeutics useful in the treatment of complement-related disorders (2021-03-16),
2. 10100316 - Aptamers comprising CPG motifs (2018-10-16),
3. 9617546 - Aptamer therapeutics useful in the treatment of complement-related disorders (2017-04-11),
4. 9303262 - Methods for identifying aptamer regulators (2016-04-05),
5. 8946184 - Aptamer therapeutics useful in the treatment of complement-related disorders (2015-02-03),
6. 8853376 - Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics (2014-10-07),
7. 8436164 - Aptamer therapeutics useful in the treatment of complement-related disorders (2013-05-07),
8. 8362234 - Solid support reagents for synthesis (2013-01-29),
9. 8236773 - Aptamer therapeutics useful in the treatment of complement-related disorders (2012-08-07),
10. 8207298 - Methods of separating biopolymer conjugated molecules from unconjugated molecules (2012-06-26),
11. 8105813 - Materials and methods for the generation of fully 2'-modified nucleic acid transcripts (2012-01-31),
12. 8101385 - Materials and methods for the generation of transcripts comprising modified nucleotides (2012-01-24),
13. 8039443 - Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics (2011-10-18),
14. 7998940 - Aptamers to von Willebrand factor and their use as thrombotic disease therapeutics (2011-08-16),
15. 7998939 - Aptamers that bind thrombin with high affinity (2011-08-16),
Company Overview
Archemix Corporation, based in Cambridge, MA, specializes in the development of aptamer-based therapeutics and diagnostics. The company focuses on harnessing the unique properties of nucleic acid ligands to create innovative solutions for various medical applications. With a strong emphasis on research and development, Archemix is dedicated to advancing the field of targeted therapies, particularly in areas such as oncology and infectious diseases, leveraging its expertise in molecular biology and biochemistry.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

24 Patents

#115 in Cambridge, MA

#834 in Massachusetts

#13,895 in US

#26,686 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Archemix Corporation

Forward Citations = 312

31 inventors:

goldMedal John Louis Diener (15 out of 34 patents)

silverMedal Charles Wilson (15 out of 16 patents)

bronzeMedal David Epstein (12 out of 15 patents)

4.  Thomas Greene McCauley (12 out of 14 patents)

5.  Claude Benedict (11 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Archemix Corporation. Retrieved from https://idiyas.com/company/archemix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…